Core Viewpoint - The company is actively pursuing several strategic initiatives that are expected to enhance its market position and profitability, including the introduction of new products and the divestiture of real estate assets [1] Group 1: Product Development and Market Potential - The company is on the verge of having Jin Nakan (金纳单抗) included in breakthrough therapy designation [1] - Anwo Gao (安沃高新) is set to commence production, with an expected annual output value of 3 billion [1] - The market for insoles and weight loss drugs is substantial, which is anticipated to generate significant profits [1] - The introduction of methylphenidate hydrochloride (盐酸右哌甲酯) is expected to tap into a large market space [1] - Jin Tuoxizhu (金妥昔单抗) and Jin Tuolizhu (金妥利珠单抗) are projected to be billion-dollar products [1] Group 2: Strategic Initiatives and Financial Management - The company is actively advancing its real estate divestiture strategy [1] - The company aims to balance expenditure to maintain stable profits [1] - The growth hormone business currently faces no competition in the market [1]